Why Alnylam Pharmaceuticals, Inc. (ALNY) stock moved
Alnylam Pharmaceuticals, Inc. (ALNY) shares tumbled 25.1% to $174.00 as of October 30, 2026, a sharp decline from the prior close of $232.40. BestStocks flagged the session as a major change for ALNY. The move is tied to an earnings beat. Below, we break down what changed for ALNY, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Earnings Beat
ALNY tumbled 25.1% in its latest session, moving from $232.40 to $174.00.
What it means for Alnylam Pharmaceuticals, Inc. investors
For Alnylam Pharmaceuticals, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Earnings beat — stock sold off (sell-the-news reaction); Positive price momentum. Weighing against that: Sharp 25.1% decline — elevated risk; High volume 6.5x on decline — distribution signal. Wall Street's consensus price target sits at $332.00, implying +90.8% upside from $174.00. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality high (90/100). With earnings roughly 104 days out, the next report is the most likely near-term test of the move.
ALNY price reaction
ALNY last traded at $174.00, down $58.40 (-25.13%) from the previous close of $232.40. The session traded on 6.5× average volume (extreme), so the move carried above-average conviction. Over the past month the stock has ranged between $174.00 and $254.07, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Alnylam Pharmaceuticals, Inc. (ALNY)
The consensus analyst price target on Alnylam Pharmaceuticals, Inc. (ALNY) is $332.00, 90.8% above the recent $174.00. Over the past 90 days analysts logged 1 upgrade, 14 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ALNY line up.
The bullish case
- Wall Street's consensus price target of $332.00 implies +90.8% upside from $174.00.
- The Street's most bullish target is $455.00 (+161.5%).
- 1 analyst upgrade in the past 90 days, most recently Raymond James to Strong Buy (2026-08-03).
- Earnings beat — stock sold off (sell-the-news reaction).
- Positive price momentum.
The bearish case
- Sharp 25.1% decline — elevated risk.
- High volume 6.5x on decline — distribution signal.
- Alnylam Pharmaceuticals reported third-quarter 2026 earnings today, revealing slower-than-expected patient demand growth for its key drug Amvuttra (vutrisiran) in ATTR cardiomyopathy despite sales force expansion, with management noting performance is trending toward the lower end of guidance ranges (investors.alnylam.com).
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 30, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for ALNY
In-depth ALNY event analyses
Frequently asked questions about ALNY
Why did Alnylam Pharmaceuticals, Inc. (ALNY) stock move?
ALNY tumbled 25.1% to $174.00. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did ALNY stock fall?
ALNY lost 25.13% ($58.40) versus the prior close of $232.40, last trading at $174.00 on 6.5× average volume.
When is Alnylam Pharmaceuticals, Inc.'s next earnings date?
ALNY's next earnings report is estimated for 2027-02-11 — about 104 days away.
What is the analyst price target for ALNY?
The consensus analyst price target for ALNY is $332.00, about 90.8% above the current $174.00. Over the past 90 days, analysts recorded 1 upgrade, 14 maintains, and 0 downgrades.
How BestStocks tracks ALNY
This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 20 tracked change events for ALNY, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 30, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.